News
Corvus Pharmaceuticals, Inc. Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the CPI-818 Phase 1/1b Clinical Trial for T Cell Lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback